Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020197505 - BIOMARKER WITH THERAPEUTIC IMPLICATIONS FOR PERITONEAL CARCINOMATOSIS

Publication Number WO/2020/197505
Publication Date 01.10.2020
International Application No. PCT/SG2020/050177
International Filing Date 27.03.2020
IPC
G01N 33/574 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
574for cancer
A61K 31/381 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
38having sulfur as a ring hetero atom
381having five-membered rings
A61P 35/04 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
04specific for metastasis
Applicants
  • SINGAPORE HEALTH SERVICES PTE LTD [SG]/[SG]
Inventors
  • ONG, Chin-Ann Johnny
  • TEO, Ching Ching Melissa
  • CHIA, Claramae Shulyn
  • TAN, Grace Hwei Ching
  • TAN, Suzanne Qiu Xuan
  • HENDRIKSON, Josephine
  • NG, Wai Har
  • TAN, Wee Shan Joey
  • LIU, Ying
Agents
  • SPRUSON & FERGUSON (ASIA) PTE LTD
Priority Data
10201902763U27.03.2019SG
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) BIOMARKER WITH THERAPEUTIC IMPLICATIONS FOR PERITONEAL CARCINOMATOSIS
(FR) BIOMARQUEUR AYANT DES IMPLICATIONS THÉRAPEUTIQUES POUR LA CARCINOMATOSE PÉRITONÉALE
Abstract
(EN)
The invention relates to method of detecting or determining susceptibility of a subject suffering from peritoneal carcinomatosis to treatment with a plasminogen activator inhibitor 1 (PAI-1) inhibitor, wherein the method comprises determining the concentration of ascites PAI-1 and determining the level of phosphorylated tumour signal transducer and activator of transcript 3 (STAT3). The level of phosphorylated STAT3 is alternatively determined by measuring the concentration of one or more surrogate markers, such as IL-6, IL-10, CCL2, MMP9, and ANGPT1, in the ascites.
(FR)
L'invention concerne un procédé pour détecter ou déterminer la sensibilité d'un sujet souffrant de carcinomatose péritonéale à un traitement avec un inhibiteur de l'activateur du plasminogène 1 (PAI-1), ledit procédé comprenant la détermination de la concentration de PAI-1 d'ascite et la détermination du niveau de transducteur de signal et activateur de transcription 3 (STAT3) tumoral phosphorylé. Le niveau de STAT3 phosphorylé est déterminé en variante par mesure de la concentration d'un ou de plusieurs marqueurs de substitution, tels que IL-6, IL-10, CCL2, MMP9 et ANGPT1, dans l'ascite.
Latest bibliographic data on file with the International Bureau